Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Edgewise Therapeutics Inc
(NQ:
EWTX
)
18.07
-0.00 (-0.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
103
Open
18.07
Bid (Size)
18.12 (3)
Ask (Size)
19.44 (4)
Prev. Close
18.08
Today's Range
18.07 - 18.07
52wk Range
5.120 - 23.50
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
September 17, 2024
From
Edgewise Therapeutics
Via
Business Wire
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024
August 08, 2024
EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
+64.32%
+64.32%
1 Month
-3.96%
-3.96%
3 Month
+11.71%
+11.71%
6 Month
+11.64%
+11.64%
1 Year
+185.55%
+185.55%
More News
Read More
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics: Q4 Earnings Insights
February 22, 2024
Via
Benzinga
How Is The Market Feeling About Edgewise Therapeutics?
January 31, 2024
Via
Benzinga
7 Small-Cap Stocks to Buy for Large-Scale Gains
July 30, 2024
Via
InvestorPlace
Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs
July 23, 2024
Via
Investor's Business Daily
Topics
Government
Exposures
Political
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
July 16, 2024
Via
Investor's Business Daily
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
May 13, 2024
Via
Investor's Business Daily
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
May 10, 2024
From
Edgewise Therapeutics
Via
Business Wire
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
May 09, 2024
Via
Benzinga
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
May 07, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
May 06, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
April 23, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
April 15, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
March 28, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
March 27, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
March 05, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
February 28, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 22, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
February 13, 2024
From
Edgewise Therapeutics
Via
Business Wire
Insider Favorites: 7 Stocks with Bullish Buying Signals
February 11, 2024
Via
InvestorPlace
Insiders Buying Edgewise Therapeutics And 2 Other Stocks
January 26, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.